GlassScriptPhysician profile
Cassandra C Latham
NPI 1568513869
$2,740.78
in general payments reported to CMS, 2019-2025
35 companies · $96.04 in 2025
The $96.04 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $899 · 2023: $820 · 2024: $85.50 · 2025: $96.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.43 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $249.15 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $204.18 | 2021-2023 | |
| Boston Scientific Corporation | $168.46 | 2021-2025 | General - Pain Management |
| Lilly USA, LLC | $164.65 | 2021-2023 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.46 | 2021-2023 | Trulance, Xifaxan |
| Pfizer INC. | $120.39 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $109.13 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.48 | 2022-2025 | |
| Horizon Therapeutics Plc | $81.61 | 2022-2023 | Krystexxa |
| Astellas Pharma US INC | $77.92 | 2021-2024 | Veozah |
| Dexcom, INC. | $76.98 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $76.76 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.66 | 2022-2023 | Rexulti |
| Medtronic, INC. | $54.89 | 2022-2024 | Venaseal, Nellcor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $52.94 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $48.16 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $47.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.54 | 2021-2023 | Breztri |
| Sunovion Pharmaceuticals INC. | $42.53 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.97 | 2022 | |
| Lundbeck LLC | $33.22 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $31.42 | 2021 | |
| Axsome Therapeutics, INC. | $30.98 | 2023 | Auvelity |
| Exact Sciences Corporation | $30.85 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $24.42 | 2023 | Spravato |
| Xeris Pharmaceuticals, INC. | $21.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.57 | 2021 | |
| Nevro Corp. | $19.38 | 2024 | Senza |
| Nestle Healthcare Nutrition INC. | $19.27 | 2021 | |
| Almatica Pharma LLC | $18.99 | 2021 | |
| Ibsa Pharma INC. | $14.29 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.56 | 2021 | |
| Neurelis, INC. | $13.21 | 2023 | Valtoco |
| Merck Sharp & Dohme LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Latham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.